Literature DB >> 33222993

Contrast-Enhanced Mammography Implementation, Performance, and Use for Supplemental Breast Cancer Screening.

Matthew F Covington1.   

Abstract

Contrast-enhanced mammography (CEM) is an emerging breast imaging technology that provides recombined contrast-enhanced images of the breast in addition to low-energy images analogous to a 2-dimensional full-field digital mammogram. Because most breast imaging centers do not use CEM at this time, a detailed overview of CEM implementation and performance is presented. Thereafter, the potential use of CEM for supplemental screening is discussed in detail, given the importance of this topic for the future of the CEM community. Diagnostic performance, safety, and cost considerations of CEM for dense breast tissue supplemental screening are discussed.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Contrast-enhanced digital mammography; Contrast-enhanced mammography; Contrast-enhanced spectral mammography; Dense breast tissue; Supplemental screening

Mesh:

Substances:

Year:  2020        PMID: 33222993     DOI: 10.1016/j.rcl.2020.08.006

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  4 in total

1.  Contrast-enhanced Mammography: An Emerging Modality in Breast Imaging.

Authors:  Manisha Bahl
Journal:  Radiology       Date:  2021-12-14       Impact factor: 11.105

Review 2.  [Artificial intelligence in breast imaging : Areas of application from a clinical perspective].

Authors:  Pascal A T Baltzer
Journal:  Radiologe       Date:  2021-01-28       Impact factor: 0.635

3.  Radiation Dose of Contrast-Enhanced Mammography: A Two-Center Prospective Comparison.

Authors:  Gisella Gennaro; Andrea Cozzi; Simone Schiaffino; Francesco Sardanelli; Francesca Caumo
Journal:  Cancers (Basel)       Date:  2022-03-31       Impact factor: 6.639

4.  The Usefulness of Spectral Mammography in Surgical Planning of Breast Cancer Treatment-Analysis of 999 Patients with Primary Operable Breast Cancer.

Authors:  Andrzej Lorek; Katarzyna Steinhof-Radwańska; Anna Barczyk-Gutkowska; Wojciech Zarębski; Piotr Paleń; Karol Szyluk; Joanna Lorek; Anna Grażyńska; Paweł Niemiec; Iwona Gisterek
Journal:  Curr Oncol       Date:  2021-07-12       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.